الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 109 |  |  |
| | | from | 109 | | |
Abstract
Oral lichen planus is a chronic mucocutaneous disorder mediated by T-cells through autocytotoxicity. Oxidative stress is also known to play a role in lichen planus pathogenesis. Lipid peroxidation is considered one of the major consequences of oxidative damage. 8-isoprostane is considered a reliable biomarker of lipid peroxidation. Lycopene is an antioxidant with various benefits on human health and was found to participate in the treatment of various oral diseases specifically oral lichen planus.
The aim of the present trial was to compare serum levels of 8-isoprostane in patients with erosive oral lichen planus (EOLP) with healthy subjects. Also, to measure those levels in patients before and after treatment with lycopene in comparison to corticosteroids. Furthermore, to evaluate and compare between the effect of both treatment modalities clinically.
In this randomized controlled clinical trial, 20 patients with clinically and histopathologically diagnosed oral erosive lichen planus and 10 healthy matched sex and age subjects were recruited. Patients were treated by different modalities for which they were divided into two equal groups:
Test (group I): Included 10 patients having severe and recalcitrant oral erosive lichen planus and were treated with pure oral lycopene capsules 10 mg once daily as a morning dose for 8 weeks.
Control (group II): Included 10 patients having severe and recalcitrant oral erosive lichen planus and were treated with oral systemic corticosteroids (prednisolone) 40 mg once daily as a morning dose for 4 consecutive weeks and the dose was tapered along another 4 weeks.
Serum levels of 8-isoprostane were measured in healthy subjects, and patients before and after treatment.
Results revealed a significant downward shift in clinical signs and symptoms at weeks 4, 8 and 20 (3 months post-treatment cessation) in the corticosteroids group and weeks 8 and 20 in the lycopene group. Inter-group comparisons revealed a significant sustained pain relief at week 20 in the lycopene as compared to the corticosteroids group. However, no significant difference was noted at other assessment times between the two groups. Comparison between serum 8-isoprostane levels showed no significant difference between healthy participants and OLP patients. At week 8, a significant reduction in 8-isoprostane levels was observed in the lycopene group from baseline and as compared to the control group. Correlation between clinical and biochemical outcomes revealed a strong positive association between pain scores and oxidative stress (8- isoprostane levels).